β3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Associated with Heart Failure (SPHERE-HF): A Double Blind, Placebo-Controlled, Randomized Clinical Trial
Open Access
- 4 December 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 25 (3) , 373-385
Abstract
Aims: Pulmonary hypertension (PH) associated with left heart disease is an increasingly prevalent problem, orphan of targeted therapies, and related to a poor prognosis, particularly when pre- and post-capillary PH combine. The current study aimed to determine whether treatment with the selective β3 adrenoreceptor agonist mirabegron improves outcomes in patients with combined pre- and post-capillary PH (CpcPH). Methods and results: The β3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure (SPHERE-HF) trial is a multicentre, randomized, parallel, placebo-controlled clinical trial that enrolled stable patients with CpcPH associated with symptomatic heart failure. A total of 80 patients were assigned to receive mirabegron (50 mg daily, titrated till 200 mg daily, n = 39) or placebo (n = 41) for 16 weeks. Of them, 66 patients successfully completed the study protocol and were valid for the main analysis. The primary endpoint was the change in pulmonary vascular resistance (PVR) on right heart catheterization. Secondary outcomes included the change in right ventricular (RV) ejection fraction by cardiac magnetic resonance or computed tomography, other haemodynamic variables, functional class, and quality of life. The trial was negative for the primary outcome (placebo-corrected mean difference of 0.62 Wood units, 95% confidence interval [CI] −0.38, 1.61, p = 0.218). Patients receiving mirabegron presented a significant improvement in RV ejection fraction as compared to placebo (placebo-corrected mean difference of 3.0%, 95% CI 0.4, 5.7%, p = 0.026), without significant differences in other pre-specified secondary outcomes. Conclusions: SPHERE-HF is the first clinical trial to assess the potential benefit of β3 adrenergic agonists in PH. The trial was negative since mirabegron did not reduce PVR, the primary endpoint, in patients with CpcPH. On pre-specified secondary outcomes, a significant improvement in RV ejection fraction assessed by advanced cardiac imaging was found, without differences in functional class or quality of life.Keywords
Funding Information
- Fundació la Marató de TV3 (20151730-31-32)
- Comunidad de Madrid (S2017/BMD-3867 RENIM-CM)
- HORIZON EUROPE European Research Council (819775)
- Ministerio de Ciencia e Innovación (PID2019-110369RB-I00)
- Instituto de Salud Carlos III (INT19/00022)
- Instituto de Salud Carlos III (PI17/00995)
- Instituto de Salud Carlos III (PI20/00742)
- European Commission
- Spanish Ministry of Science and Innovation
- Ministerio de Ciencia, Innovación y Universidades
- Pro CNIC Foundation
- Severo Ochoa Center of Excellence (CEX2020-001041-S)
- Generalitat de Catalunya
- Fundació la Marató de TV3 (Grant/Award Number: 20151730‐31‐32)
- Comunidad de Madrid (Grant/Award Number: S2017/BMD‐3867 RENIM‐CM)
- HORIZON EUROPE European Research Council (Grant/Award Number: 819775)
- Ministerio de Ciencia e Innovación (Grant/Award Number: PID2019‐110369RB‐I00)
- Instituto de Salud Carlos III (Grant/Award Numbers: INT19/00022)
- Instituto de Salud Carlos III (PI17/00995)
- Instituto de Salud Carlos III (PI20/00742)
- European Commission
- Ministerio de Ciencia e Innovación
- Ministerio de Ciencia, Innovación y Universidades
- Generalitat de Catalunya
This publication has 52 references indexed in Scilit:
- Cardioprotective Effect of Beta-3 Adrenergic Receptor AgonismJACC, 2012
- Pulmonary Pressures and Death in Heart FailureJACC, 2012
- Beta3-Adrenoreceptor Stimulation Ameliorates Myocardial Ischemia-Reperfusion Injury Via Endothelial Nitric Oxide Synthase and Neuronal Nitric Oxide Synthase ActivationJACC, 2011
- New perspectives for the treatment of pulmonary hypertensionBritish Journal of Pharmacology, 2011
- PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart FailureCirculation: Heart Failure, 2011
- Determinants of Right Ventricular Ejection Fraction in Pulmonary Arterial HypertensionChest, 2009
- Pulmonary Hypertension in Heart Failure With Preserved Ejection FractionJACC, 2009
- The analysis of continuous outcomes in multi‐centre trials with small centre sizesStatistics in Medicine, 2007
- Endothelial β 3 -Adrenoceptors Mediate Vasorelaxation of Human Coronary Microarteries Through Nitric Oxide and Endothelium-Dependent HyperpolarizationCirculation, 2004
- Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?International Journal of Cardiology, 2002